IL6 and fungal infectious disease: Studies regarding safety surveillance of biologic therapies, such as TNF-a inhibitors, biologic drugs targeting proinflammatory cytokines [interleukin (IL)-1, IL-6], anti-B-cell depletion therapies, and Janus kinase inhibitors (JAKis), showed, especially for fungal infections, that the hazard may be limited, if not underestimated.